• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases.

作者信息

Piantino P, Andriulli A, Gindro T, Pecchio F, Masoero G, Cavallini G, Naccarato R, Dobrilla G

出版信息

Am J Gastroenterol. 1986 Jun;81(6):436-9.

PMID:3458359
Abstract

Levels of a new carbohydrate antigen CA 19-9, which is a monosialoganglioside identified by a monoclonal antibody raised against colorectal carcinoma cells, were compared to carcinoembryonic antigen and tissue polypeptide antigen assays in 250 sera from patients with different pancreatic diseases including acute pancreatitis, chronic pancreatitis, and pancreatic cancer. All three tumoral markers were elevated at the onset of an acute pancreatic attack in a few patients. All but five patients with chronic pancreatitis displayed normal levels with each of the three markers; in two of these five cases an extraintestinal cancer was later discovered. CA 19-9 displayed higher sensitivity and predictive value of a negative result than the other two markers. The best operational characteristic of CA 19-9 was its high predictive value for a positive test which suggests a "ruling in" usage of it for pancreatic cancer diagnosis. CA 19-9 assay was of extreme value in disclosing both localized and metastatic pancreatic cancer while the other two markers were more often positive in the latter case. Of 71 cancer patients with positive markers, only four would have escaped a right diagnosis by assaying CA 19-9 alone.

摘要

相似文献

1
CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases.
Am J Gastroenterol. 1986 Jun;81(6):436-9.
2
Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.胰腺癌患者纯胰液中糖类抗原(CA)19-9水平的测定。
Am J Gastroenterol. 1988 Feb;83(2):126-9.
3
Serum markers and clinical data in diagnosing pancreatic cancer: a contrastive approach.
Am J Gastroenterol. 1988 May;83(5):549-53.
4
Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.多种胰腺疾病中血清胰酶、糖类抗原19-9及癌胚抗原的评估
Am J Gastroenterol. 1985 Aug;80(8):630-6.
5
Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.组织多肽抗原(TPA)在胰腺癌诊断中的临床评估
Anticancer Res. 1993 Sep-Oct;13(5C):1883-7.
6
[The role of CEA, CA 19-9 and TPA in the diagnosis of pancreatic cancer. Evaluation by discriminant analysis].[癌胚抗原、糖类抗原19-9和组织多肽抗原在胰腺癌诊断中的作用。判别分析评估]
Minerva Med. 1986 Apr 14;77(16):613-6.
7
Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.
Acta Chir Scand. 1987 Jan;153(1):45-9.
8
Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases.胰腺疾病中胰液和血清的多参数肿瘤标志物(CA 19-9、癌胚抗原、甲胎蛋白、胰癌胚抗原)分析
Hepatogastroenterology. 1985 Jun;32(3):141-5.
9
Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.胰腺癌中肿瘤标志物CA 242与CA 19-9及癌胚抗原(CEA)的比较。
Hepatogastroenterology. 2003 Sep-Oct;50(53):1669-74.
10
[Tumor markers of pancreatic cancer].[胰腺癌的肿瘤标志物]
Gan To Kagaku Ryoho. 1985 Feb;12(2):212-9.

引用本文的文献

1
The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.CA19-9 在胰腺腺癌中的临床应用:诊断和预后更新。
Curr Mol Med. 2013 Mar;13(3):340-51. doi: 10.2174/1566524011313030003.
2
Relapsed acute pancreatitis as the initial presentation of pancreatic cancer in a young man: a case report.初发急性胰腺炎后复发为青年胰腺癌的临床表现:一例报告
Kaohsiung J Med Sci. 2010 Aug;26(8):448-55. doi: 10.1016/S1607-551X(10)70072-3.
3
Consensus on the treatment of pancreatic cancer in Spain.西班牙胰腺癌治疗共识
Clin Transl Oncol. 2009 May;11(5):290-301. doi: 10.1007/s12094-009-0357-3.
4
Carcinoma of the head of the pancreas versus chronic pancreatitis: diagnostic dilemma with significant consequences.胰头癌与慢性胰腺炎:存在重大后果的诊断困境。
World J Surg. 2003 Nov;27(11):1249-57. doi: 10.1007/s00268-003-7245-8. Epub 2003 Oct 13.
5
"Mass-forming" pancreatitis masquerades as pancreatic carcinoma.肿块型胰腺炎常伪装成胰腺癌。
Int J Pancreatol. 1996 Aug;20(1):27-35. doi: 10.1007/BF02787373.
6
Elevated serum levels of tumor marker CA19-9 in acute cholangitis.
Dig Dis Sci. 1988 Oct;33(10):1223-5. doi: 10.1007/BF01536670.
7
Enzyme-linked PNA lectin binding assay compared with CA19-9 and CEA radioimmunoassay as a diagnostic blood test for pancreatic cancer.将酶联肽核酸凝集素结合试验与CA19-9和癌胚抗原放射免疫测定法相比较,作为胰腺癌的诊断性血液检测方法。
Br J Cancer. 1989 Jun;59(6):949-53. doi: 10.1038/bjc.1989.202.
8
Prospective trial for early detection of pancreatic cancer by elevated serum immunoreactive elastase.通过血清免疫反应性弹性蛋白酶升高早期检测胰腺癌的前瞻性试验。
Gastroenterol Jpn. 1990 Dec;25(6):727-31. doi: 10.1007/BF02779187.